FDA Clears Trial for Wearable Hat Device to Treat Treatment-Resistant Depression

Wake up. Brush your teeth. Wash your face. And put on your lifesaving baseball hat.

That’s the vision for patients with treatment-resistant depression, courtesy of neurotech startup Motif Neurotech. The company’s wearable device—a baseball cap—would activate a blueberry-sized implant in the skull, delivering targeted electrical pulses to the brain.

On Friday, the U.S. Food and Drug Administration (FDA) approved Motif Neurotech’s request to begin an initial feasibility trial. The trial will evaluate the safety and efficacy of the company’s neurostimulation device for treating depression that has not responded to other therapies.

How the Device Works

Motif Neurotech’s approach builds on transcranial magnetic stimulation (TMS), a decades-old technique used to alleviate depression by stimulating brain activity. Unlike traditional TMS, which uses external coils, Motif’s system combines:

• A surgically implanted neurostimulator (the size of a blueberry)
• A wearable baseball cap that activates the implant
• Targeted electrical pulses to modulate brain circuits linked to depression

The device is designed to be worn daily, offering a non-invasive alternative to other neuromodulation therapies.

FDA Approval Marks a Milestone

The FDA’s clearance for the feasibility trial is a critical step for Motif Neurotech. The company, led by founder and CEO Jacob Robinson, aims to demonstrate the device’s potential to help the estimated 280 million people worldwide living with depression, including those who do not respond to medication or therapy.

“This is a game-changer for patients who have exhausted all other options,” Robinson said in a statement. “Our goal is to provide a safe, effective, and accessible treatment for treatment-resistant depression.”

Next Steps in the Trial

The initial feasibility trial will enroll a small group of participants to assess the device’s safety and preliminary efficacy. If successful, Motif Neurotech plans to expand testing in larger clinical studies.

For now, patients with treatment-resistant depression may soon have a new option—one that starts with a simple step: putting on a hat.